Carl Awh, MD
Retina Specialist · Nashville, TNNPI 1386729085
Payments from drug & device makers
Across 987 payments — averaging $9775.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$6.5M
- Ocular Therapeutix, Inc.$1.4M
- Apellis Pharmaceuticals, Inc.$553K
- Bausch & Lomb Americas Inc.$471K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$410K
- US Retina LLC$67K
- plus $275K from 23 others
Across 24 payments — averaging $2843.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$56K
- Ocular Therapeutix, Inc.$10K
- Genentech, Inc.$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 497 | $6,476,286 |
| Ocular Therapeutix, Inc. | 122 | $1,397,405 |
| Apellis Pharmaceuticals, Inc. | 140 | $552,602 |
| Bausch & Lomb Americas Inc. | 36 | $470,590 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 24 | $410,309 |
| US Retina LLC | 11 | $67,057 |
| Astellas Pharma Global Development | 5 | $66,247 |
| Genentech USA, Inc. | 49 | $59,308 |
| F. Hoffmann-la Roche AG | 16 | $44,090 |
| Glaukos Corporation | 1 | $27,241 |
| Amgen | 9 | $23,814 |
| Roche Products Limited | 4 | $22,891 |
| AbbVie(2 entities) | 14 | $11,462 |
| Katalyst Surgical, LLC | 8 | $9,662 |
| Novartis | 5 | $4,592 |
| Carl Zeiss Meditec, Inc. | 3 | $1,483 |
| Dutch Ophthalmic Research Center (international) B.v. | 5 | $1,083 |
| Regeneron Healthcare Solutions, Inc. | 10 | $851 |
| Astellas Pharma US Inc | 8 | $549 |
| Harrow Eye, LLC | 3 | $458 |
| Dutch Ophthalmic, USA | 1 | $140 |
| Coherus Oncology, Inc. | 1 | $134 |
| Neurotech Pharmaceuticals, Inc. | 1 | $125 |
| Biogen | 2 | $118 |
| Alimera Sciences, Inc. | 6 | $115 |
| Eyepoint US, Inc. | 3 | $72 |
| Iridex Corporation | 1 | $71 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Regeneron | 1 | $12 |
How this compares
$9,648,794 in reported general payments places this provider in the 95th percentile of 58 retina specialist providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other retina specialist in Nashville
- Eric SchneiderNashville$4M
- Brandon BusbeeNashville$1.7M
- Peter SonkinNashville$949K
- Akshay ThomasNashville$807K
- Everton ArrindellNashville$279K
- David ReichsteinNashville$176K
- Marcus SolomonNashville$114K
- Brigid MarshallNashville$105K
- Franco RecchiaNashville$72K
- Roy WallaceNashville$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.